Search results for "HEPATITIS"

showing 10 items of 1578 documents

Seasonal and spatial dynamics of enteric viruses in wastewater and in riverine and estuarine receiving waters

2018

International audience; Enteric viruses represent a global public health threat and are implicated in numerous foodborne andwaterborne disease outbreaks. Nonetheless, relatively little is known of their fate and stability in the environment. In this studywe used carefully validatedmethods tomonitor enteric viruses, namely adenovirus (AdV), JC polyomavirus (JCV), noroviruses (NoVs), sapovirus (SaV) and hepatitis A and E viruses (HAV and HEV) fromwastewater source to beaches and shellfish beds. Wastewater influent and effluent, surface water, sediment and shellfish samples were collected in the Conwy catchment (North Wales, UK) once a month for one year. High concentrations of AdV and JCV wer…

0301 basic medicineVeterinary medicineviruses010501 environmental sciencesWastewater01 natural sciencesWaste Disposal Fluid[SDV.IDA]Life Sciences [q-bio]/Food engineeringhuman adenovirusWaste Management and Disposalmurine norovirusbiologyhepatitis-eWaterborne diseasesvirus diseasesContaminationHepatitis EPollution6. Clean water3. Good healthqPCRWastewaterHealthdiverse microbes[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologySeasonsWater MicrobiologyTangential flow ultrafiltrationEnvironmental MonitoringPorcine gastric mucin assayEnvironmental Engineering030106 microbiologydrinking-waterblood group antigensViral survival03 medical and health sciencesEnteric virus trackingmedicineEnvironmental ChemistryEffluentShellfish0105 earth and related environmental scienceshuman polyomavirusviral gastroenteritisWater PollutionOutbreakSapovirusFaecal contaminationbiology.organism_classificationmedicine.diseaseBiology and Microbiologyporcine gastric mucinsimultaneous recovery
researchProduct

Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice

2018

Fibrosis remains a serious health concern in patients with chronic liver disease. We recently reported that chemically induced chronic murine liver injury triggers increased expression of junctional adhesion molecules (JAMs) JAM-B and JAM-C by endothelial cells and de novo synthesis of JAM-C by hepatic stellate cells (HSCs). Here, we demonstrate that biopsies of patients suffering from primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) or autoimmune hepatitis (AIH) display elevated levels of JAM-C on portal fibroblasts (PFs), HSCs, endothelial cells and cholangiocytes, whereas smooth muscle cells expressed JAM-C constitutively. Therefore, localization and function of JA…

0301 basic medicine[SDV]Life Sciences [q-bio]Cholangitis SclerosingMyocytes Smooth MuscleeducationImmunologyImmunoglobulinsAutoimmune hepatitisVascular RemodelingChronic liver diseaseMural cellPrimary sclerosing cholangitisFatty Acids MonounsaturatedMice03 medical and health sciencesFibrosisCell AdhesionmedicineAnimalsHumansImmunology and AllergyMyofibroblastsCells CulturedInflammationMice KnockoutFibrous capsule of GlissonLiver Cirrhosis Biliarybusiness.industryfungiEndothelial Cellsmedicine.diseaseFibrosishumanities3. Good healthMice Inbred C57BLDisease Models AnimalHepatitis Autoimmune030104 developmental biologyLiverVasoconstrictioncardiovascular systemCancer researchHepatic stellate cellFemaleHepatic fibrosisbusinessCell Adhesion MoleculesJournal of Autoimmunity
researchProduct

Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis

2020

International audience; Kupffer cells (KCs) are liver-resident macrophages that self-renew by proliferation in the adult independently from monocytes. However, how they are maintained during non-alcoholic steatohepatitis (NASH) remains ill defined. We found that a fraction of KCs derived from Ly-6C+ monocytes during NASH, underlying impaired KC self-renewal. Monocyte-derived KCs (MoKCs) gradually seeded the KC pool as disease progressed in a response to embryo-derived KC (EmKC) death. Those MoKCs were partly immature and exhibited a pro-inflammatory status compared to EmKCs. Yet, they engrafted the KC pool for the long term as they remained following disease regression while acquiring matur…

0301 basic medicine[SDV]Life Sciences [q-bio]OntogenyMESH: Cell Self RenewalSelf renewalMESH: MonocytesMESH: Mice KnockoutMice0302 clinical medicineNon-alcoholic Fatty Liver DiseaseImmunology and AllergyKupffer cellsMESH: AnimalsCell Self RenewalMESH: Lipid MetabolismMice KnockoutKupffer cellLipidsResearch Highlightmacrophages[SDV] Life Sciences [q-bio]Infectious Diseasesmedicine.anatomical_structureLiver030220 oncology & carcinogenesismonocytesmedicine.medical_specialtynon-alcoholic steatohepatitis (NASH)ImmunologyBiology03 medical and health sciencesMESH: Mice Inbred C57BLMESH: Cell ProliferationInternal medicinemedicineAnimalsLiver damageMESH: MiceCell ProliferationMESH: Non-alcoholic Fatty Liver DiseaseTriglyceride storageNon alcoholicLipid Metabolismmedicine.diseaseMESH: Lipidseye diseasesMice Inbred C57BLMESH: Kupffer Cells030104 developmental biologyEndocrinologySteatohepatitisHomeostasisMESH: LiverImmunity
researchProduct

Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwid…

2015

ABSTRACTThere is no comprehensive study available on the natural hepatitis C virus (HCV) polymorphism in sites associated with resistance including all viral genotypes which may present variable susceptibilities to particular direct-acting antivirals (DAAs). This study aimed to analyze the frequencies, genetic barriers, and evolutionary histories of naturally occurring resistance-associated variants (RAVs) in the six main HCV genotypes. A comprehensive analysis of up to 103 RAVs was performed in 2,901, 2,216, and 1,344 HCV isolates for the NS3, NS5A, and NS5B genes, respectively. We report significant intergenotypic differences in the frequencies of natural RAVs for these three HCV genes. I…

0301 basic medicineanimal structuresHepatitis C virusHepacivirusMutation MissenseGenome ViralHepacivirusViral Nonstructural Proteinsmedicine.disease_causeAntiviral Agents03 medical and health scienceschemistry.chemical_compoundGenotypeDrug Resistance ViralmedicineHumansPharmacology (medical)NS5AGeneNS5BPharmacologyGeneticsNS3Polymorphism GeneticbiologyHaplotypevirus diseasesChromosome MappingHepatitis C Chronicbiology.organism_classificationVirologydigestive system diseases030104 developmental biologyInfectious DiseaseschemistryHaplotypesAntimicrobial agents and chemotherapy
researchProduct

Host Cell Rab GTPases in Hepatitis B Virus Infection

2018

Hepatitis B virus (HBV) is a leading cause of liver disease and is presently estimated to infect more than 250 million humans. The extremely successful spread of this virus among the human population is explained by its effective transmission strategies and its manifold particle types, including virions, empty envelopes and naked capsids. Due to its tiny genome, HBV depends on cellular machineries to thrive in infected hepatocytes. To enter, traverse and exit the cell, HBV exploits host membrane trafficking pathways, including intracellular highways directed by Rab GTPases. Here, we review recent discoveries focused on how HBV co-opts and perturbs host Rab GTPase functions with an emphasis …

0301 basic medicineautophagyPopulationvirus assemblyReviewGTPaseBiologymedicine.disease_causeVirusRab33BCell and Developmental Biology03 medical and health sciencesViral life cyclemedicineHBVeducationlcsh:QH301-705.5Hepatitis B viruseducation.field_of_studyRab effector030102 biochemistry & molecular biologyEffectorCell BiologyRab7ARab GAPCell biology030104 developmental biologyRAB7Avirus traffickinglcsh:Biology (General)RabDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Can we prevent and modify cardiometabolic disorders by controlling HCV infection?

2017

HCV infection has an estimated global prevalence of 1.0%, corresponding to roughly 71.1 million of infected individuals in 2015, with major geographical heterogeneity.1 Due to the large burden of infected individuals in the general population, the likelihood of co-occurrence of chronic HCV infection and common comorbidities is substantial regardless of causal linkages. Population-based studies show a higher overall mortality, both for liver-related and unrelated causes in HCV infected subjects compared with those uninfected, and cross-sectional and cohort studies identify HCV as an independent risk factor for extrahepatic manifestations.2 These issues are summarised in two meta-analyses rep…

0301 basic medicineeducation.field_of_studybusiness.industryPopulationGastroenterologyHepatitis CType 2 diabetesDiseasemedicine.diseaseHepatitis C03 medical and health sciences030104 developmental biology0302 clinical medicineDiabetes mellitusCardiovascular DiseaseImmunologyMedicine030211 gastroenterology & hepatologyPorphyria cutanea tardaRisk factorbusinesseducationCohort study
researchProduct

Real life experiences in HCV management in 2018

2019

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimiza…

0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusiness
researchProduct

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.

2021

Due to the improved effectiveness and safety of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection has become a manageable, chronic condition rather than a mortal disease. However, HIV patients are at increased risk of experiencing non-AIDS-defining illnesses, with liver-related injury standing out as one of the leading causes of death among these patients. In addition to more HIV-specific processes, such as antiretroviral drug-related toxicity and direct injury to the liver by the virus itself, its pathogenesis is related to conditions that are also common in the general population, such as alcoholic and non-alcoholic fatty liver disease, viral hepatitis, and age…

0301 basic medicinehepatotoxicityNevirapineEfavirenzQH301-705.5030106 microbiologyEtravirinecARTReviewBioinformaticsliver03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineDoravirinemedicineAnimalsHumans030212 general & internal medicineBiology (General)antiretroviral drugsbusiness.industryFatty livervirus diseasesHIVGeneral Medicinemedicine.diseasechemistryRilpivirineChronic DiseaseReverse Transcriptase InhibitorsDrug Therapy CombinationDILIChemical and Drug Induced Liver InjuryViral hepatitisbusinessmedicine.drugCells
researchProduct

Hepatocellular carcinoma and direct-acting antivirals: A never ending story?

2017

0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsClinical Decision-MakingDIRECT ACTING ANTIVIRALSAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansHepatologybusiness.industryIncidencePatient SelectionLiver NeoplasmsHepatitis C ChronicHepatologymedicine.diseaseLiver TransplantationTreatment Outcome030104 developmental biologyHepatocellular carcinomaCancer research030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.

2016

Background & Aims The pathomechanisms underlying non-alcoholic fatty liver disease (NAFLD) and the involved molecular regulators are incompletely explored. The nuclear factor-kappa B (NF-κB)-cofactor gene B cell leukemia-3 ( Bcl-3 ) plays a critical role in altering the transcriptional capacity of NF-κB – a key inducer of inflammation – but also of genes involved in cellular energy metabolism. Methods To define the role of Bcl-3 in non-alcoholic steatohepatitis (NASH), we developed a novel transgenic mouse model with hepatocyte-specific overexpression of Bcl-3 ( Bcl-3 Hep ) and employed a high-fat, high-carbohydrate dietary feeding model. To characterize the transgenic model, deep RNA seque…

0301 basic medicinemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentBiology03 medical and health sciencesLiver diseaseMice0302 clinical medicineB-Cell Lymphoma 3 ProteinInternal medicineProto-Oncogene ProteinsmedicineAnimalsHumansInsulinInflammationHepatologyInsulinLiver cellFatty liverLiver Neoplasmsmedicine.disease030104 developmental biologyEndocrinology030220 oncology & carcinogenesisLipogenesisSteatohepatitisSteatosisTranscription FactorsJournal of hepatology
researchProduct